ロード中...
Targeting cancer with antibody-drug conjugates: Promises and challenges
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...
保存先:
| 出版年: | MAbs |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8300931/ https://ncbi.nlm.nih.gov/pubmed/34291723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2021.1951427 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|